GlobeNewswire by notified

Invitation to UPM’s webcast and press conference on Q1 2022 Interim Report

Share

(UPM, Helsinki, 19 April 2022 at 13:00 EEST) – UPM will publish its Q1 2022 Interim Report on 26 April 2022 at 09:30-10:00 EEST. After publishing the report will be available on company's website at www.upm.com.

A webcast and a conference call for analysts and investors in English language begins at 13:15 EEST. UPM’s financial results will be presented by the President and CEO Jussi Pesonen and CFO Tapio Korpeinen. All participants can view the webcast online at www.upm.com or through this link, but participants who wish to ask questions must attend the conference call by dialling a number in the list below:

Conference call title: UPM Interim Report for January–March 2022
International telephone numbers:

Dial in number(s)
Argentina Toll: +54 1152526536
Australia Toll: +61 284058549
Austria Toll: +43 19287907
Belgium Toll: +32 24035814
Brazil Toll: +55 1133517266
Bulgaria Toll: +359 29358129
Canada Toll: +1 4162164189
Chile Toll: +56 226188227
China Toll: +86 4008983300
Croatia Toll: +385 20770084
Cyprus Toll: +357 26030115
Czech Republic Toll: +420 225439714
Denmark Toll: +45 35445577
Estonia Toll: +372 6868838
Finland Toll: +358981710310
France Toll: +33 170750711
Germany Toll: +49 6913803430
Greece Toll: +30 2112111509
Hong Kong Toll: +852 30600225
Hungary Toll: +36 12355213
India Toll: +91 2271279610
Indonesia Toll: +62 2129704955
Ireland Toll: +353 15251892
Israel Toll: +972 37207679
Italy Toll: +39 0236013821
Japan Toll: +81 344556492
Korea, Republic Of Toll: +82 234798456
Latvia Toll: +371 67852162
Lithuania Toll: +370 52051171
Luxembourg Toll: +352 27300160
Malaysia Toll: +60 320531815
Morocco Toll: 212520480069
Netherlands Toll: +31 207095189
New Zealand Toll: +64 93670511
Norway Toll: +47 23500243
Philippines Toll: 63285400965
Poland Toll: +48 225839017
Portugal Toll: +351 210609105
Russian Federation Toll: +7 4959909265
Saudi Arabia Toll: +966 115108758
Singapore Toll: +6564085767
Slovakia Toll: +421 250112045
Slovenia Toll: +386 18888475
South Africa Toll: +27 216724118
Spain Toll: +34 935472900
Sweden Toll: +46 856642651
Switzerland Toll: +41 225809034
Taiwan Toll: +886 287231159
Turkey Toll: +90 2123755124
Ukraine Toll: +380 893239875
United Kingdom Toll: +44 3333000804
United States Toll: +1 6319131422
Venezuela Toll: +58 2123358975
Viet Nam Toll: +1 8882064044

PIN code: 78465553#

We recommend that participants dial in 5-10 minutes prior to ensure a timely start of the webcast. The webcast will be available at www.upm.com for 12 months after the call.

Later in the afternoon, at 14:45 EEST, CEO Jussi Pesonen will present the Q1 results in a press conference held in the Finnish language both at the Biofore House and online. Due to the Covid-19 pandemic, participation to the Biofore House event is restricted to members of the media only

For more information, please contact:

UPM, Investor Relations
Mon–Fri from 9:00 to 16:00 EEST
tel. +358 20 415 0033
ir@upm.com

UPM, Media Relations
Mon–Fri from 9:00 to 16:00 EEST
tel. +358 40 588 3284
media@upm.com

UPM
We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Fibres, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility, we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 17,000 people worldwide and our annual sales are approximately EUR 9.8 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com

Follow UPM on Twitter | LinkedIn | Facebook | YouTube | Instagram | #UPM #biofore #beyondfossils

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

IBFD launches the 2021 Yearbook on Taxpayers’ Rights19.5.2022 10:00:00 CEST | Press release

Today, IBFD launches the 2021 Yearbook on the Protection of Taxpayers’ Rights (OPTR). The book is a compilation of up-to-date information on the effective protection of taxpayers’ rights. AMSTERDAM, May 19, 2022 (GLOBE NEWSWIRE) -- Prof. Dr Pasquale Pistone and Prof. Dr Philip Baker, Directors of IBFD’s OPTR, will present the Yearbook at the 7th International Conference on Taxpayer Rights, hosted by the Center for Taxpayer Rights, explaining some of the main events and trends that arose last year in the protection of taxpayers’ rights around the world. Click here to watch the video. The OPTR reports on the protection of taxpayers’ fundamental rights around the world. The precise and technical information of the OPTR contains reference to taxpayer bills, conventions and statutes, including their judicial and administrative interpretation, which explore how states apply this protection in practice. The OPTR serves as a unique legal basis for developing further research on the legal remed

Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics19.5.2022 10:00:00 CEST | Press release

Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) -- Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistanceThe company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry AllianceThis achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics. Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral

Share Buyback Transaction Details May 12 – May 18, 202219.5.2022 10:00:00 CEST | Press release

Share Buyback Transaction Details May 12 – May 18, 2022 May 19, 2022 - Wolters Kluwer today reports that it has repurchased 118,000 of its own ordinary shares in the period from May 12, 2022, up to and including May 18, 2022, for €11.0 million and at an average share price of €92.92. These repurchases are part of the share buyback program announced on February 23, 2022, under which we intend to repurchase shares for up to €600 million during 2022. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2022 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€) 2022 to date 2,573,464 238.4 92.64 For the period starting May 5, 2022, up to and including August 1, 2022, we have engaged a third party to execute €140 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association. Repurchased shares are add

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)19.5.2022 09:01:00 CEST | Press release

Dante Labs is a Global Leader in Genomics and Precision MedicineMainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC). Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to co

Regarding the approval of the key financial performance indicators for AB Klaipėdos nafta for the period of 2022-202419.5.2022 08:22:29 CEST | Press release

AB Klaipėdos nafta (hereinafter – the Company) hereby informs that the Government of the Republic of Lithuania on 18 May 2022 adopted the resolution No. 509 “Regarding the approval of the key financial performance indicators for state-owned enterprises for the period of 2022-2024”, which establishes the following performance indicators for the Company: Indicator202220232024Average annual adjusted EBITDA* Period 2022–2024 ≥ EUR 33.9 millionAnnual financial debt to equity ratio Period 2022–2024 limit 1.7–3.2 times * EBITDA less adjustment (temporary regulatory differences, temporary fluctuations in the fair value of financial derivatives, results from disposal or revaluation of non-current assets, compensations received for previous periods, other non-typical corrections). Mindaugas Kvekšas, Chief Financial Officer, +370 46 391772